The last two years might have been a challenging time for many people but also an opportunity particular for biotech startups, when this pandemic is over, will the valuations come crashing down, revenue growth be slowed down? If yes, what & how should biotech startups prepare for this? - Joseph Fung from Saltagen Ventures